| Washington University in St. Louis | |
|---|---|
| WashU Logo | |
| Location | St. Louis, Missouri, USA |
| Type | Private Research University |
| Founded | 1853 |
| Website | wustl.edu |
| Focus Areas | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), Dementia, Neuroimaging, Genetics |
| Medical School | [Washington University School of Medicine](/institutions/washu-school-of-medicine) |
Washington University In St. Louis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Washington University in St. Louis (WashU) is one of the world's leading private research universities, founded in 1853. Its School of Medicine is consistently ranked among the top in the nation for neuroscience and neurodegeneration research. The university's Knight Alzheimer's Disease Research Center (ADRC) is one of the original NIH-funded ADRCs and has been instrumental in defining the preclinical and prodromal stages of Alzheimer's disease[1].
WashU's neuroscience community benefits from close integration between the School of Medicine, the Division of Biological Sciences, and the School of Engineering, enabling multidisciplinary approaches to neurodegeneration.
The Knight ADRC, directed by Dr. John Morris, has defined the preclinical Alzheimer's disease cascade and developed biomarker criteria now used worldwide. The center contributes to the Alzheimer's Clinical Trials Consortium and has pioneered cerebrospinal fluid and PET biomarker discovery[2].
The Hope Center focuses on understanding the basic biology of neurological disorders, including Alzheimer's, Parkinson's, ALS, and multiple sclerosis. Research spans from molecular mechanisms to translational therapeutics[3].
WashU leads the international DIAN observational study and clinical trials for individuals with autosomal dominant Alzheimer's disease mutations, providing unique insights into disease pathogenesis decades before symptom onset.
| Disease | Research Intensity |
|---|---|
| Alzheimer's Disease | Very High |
| Parkinson's Disease | High |
| ALS | Moderate |
| Frontotemporal Dementia | Moderate |
| Huntington's Disease | Low |
WashU offers extensive training through the Neuroscience Program, the MD/PhD Program, and the Postdoctoral Training Program in neurodegeneration.
The Knight ADRC, established in 1985 as one of the original NIH-funded Alzheimer's Disease Research Centers, has been a pioneer in Alzheimer's disease research. Directed by Dr. John Morris since its inception, the center has made seminal contributions to understanding the preclinical and prodromal stages of AD[2:1]. The Knight ADRC has been instrumental in developing the biomarker framework that now defines the field's research framework, particularly through the influential NIA-AA research framework[4].
The Knight ADRC has led the development and validation of key AD biomarkers:
The center defined the concept of preclinical AD:
The Dominantly Inherited Alzheimer Network (DIAN)[7] is an international observational study and clinical trials platform led by Washington University. DIAN studies individuals with autosomal dominant AD mutations (APP, PSEN1, PSEN2) who have a predictable age of onset.
The Hope Center for Neurological Disorders[3:1] brings together basic and clinical researchers to understand neurological disorders including:
Led by Dr. David Holtzman[8], this program focuses on:
Led by Dr. Celeste Karch[9] and Dr. Carlos Cruchaga[10]:
Interdisciplinary center integrating:
Advanced neuroimaging capabilities:
Comprehensive biomarker services:
Director, Knight ADRC; Pioneer in preclinical AD biomarkers:
Director, DIAN; Expert in amyloid and tau kinetics:
Tau biology and immunotherapy:
Genetic architecture of AD and ALS:
Genomics and bioinformatics:
Comprehensive clinical care and research:
Focused on DLB and AD overlap[11]:
WashU offers extensive training:
| Year | Finding | Impact |
|---|---|---|
| 2006 | First amyloid PET in humans[5:1] | Established PET as AD biomarker |
| 2010 | DIAN study design[12] | Enabled preclinical AD trials |
| 2018 | NIA-AA Framework[4:1] | Global research standard |
| 2020 | CSF biomarkers review[13] | Clinical implementation guide |
| 2022 | DIAN biomarker findings[7:1] | Preclinical AD pathophysiology |
| 2023 | Preclinical AD update[2:2] | Current best practices |
Morris JC et al. Preclinical AD: Update on biomarkers and prevention. Nat Rev Neurol. 2023. ↩︎ ↩︎ ↩︎
Jack CR Jr et al. NIA-AA Research Framework: Alzheimer's disease. Alzheimers Dement. 2018. ↩︎ ↩︎
Mintun MA et al. [11C]PIB in young adults (2006). 2006. ↩︎ ↩︎
Rowe CC et al. Amyloid imaging with PET in aging and AD (2007). 2007. ↩︎
Bateman RJ et al. Dominantly Inherited Alzheimer Network: Clinical and biomarker findings. Nat Med. 2022. ↩︎ ↩︎
Holtzman DM et al. Tau in Alzheimer disease and related tauopathies. Nat Rev Neurol. 2021. ↩︎
Karch CM et al. Genetic architecture of Alzheimer's disease. Mol Psychiatry. 2018. ↩︎
Cruchaga C et al. Genomic insights into Alzheimer disease. Nat Rev Neurol. 2020. ↩︎
Poston KL et al. DLB and AD overlap (2013). 2013. ↩︎
Masel AM et al. DIAN study design (2010). 2010. ↩︎
Schindler SE et al. CSF biomarkers in Alzheimer disease. Nat Rev Neurol. 2019. ↩︎